BG
EGRX

BlackRock Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

BlackRock Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1.18M Buy
14,797
+5,055
+52% +$367K ﹤0.01% 2055
2016
Q3 		$682K Buy
9,742
+6,872
+239% +$381K ﹤0.01% 2203
2016
Q2 		$111K Sell
2,870
-46
-2% -$1.92K ﹤0.01% 2767
2016
Q1 		$118K Buy
2,916
+1,126
+63% +$71.4K ﹤0.01% 2713
2015
Q4 		$159K Sell
1,790
-1,938
-52% -$153K ﹤0.01% 2573
2015
Q3 		$276K Sell
3,728
-5,411
-59% -$450K ﹤0.01% 2424
2015
Q2 		$739K Buy
+9,139
New +$595K ﹤0.01% 2107

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

BlackRock Group's EGRX Position: Q4 2016 in Review

BlackRock Group increased its Eagle Pharmaceuticals, Inc. (EGRX) stake by 52% in Q4 2016, buying an estimated $367K and bringing the position to 14,797 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2055.

BlackRock Group first reported a position in EGRX in Q2 2015 and has held it in 7 quarters since. 149 funds tracked by Wall St. Rank hold EGRX as of Q4 2016.

  • BlackRock Group held 14,797 shares of Eagle Pharmaceuticals, Inc. worth $1.18M as of Q4 2016.
  • BlackRock Group bought 5,055 Eagle Pharmaceuticals, Inc. shares in Q4 2016, an estimated $367K.
  • Eagle Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2055 holding.
  • BlackRock Group first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and has held it in 7 quarters since.
  • 149 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.